ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.

圣路易斯，2023年11月23日（GLOBE NEWSWIRE）-核医学全球领导者Curium今天宣布，在关键的3期ECLIPSE试验中成功完成患者入选。ECLIPSE是一项3期，多中心，开放标签的随机临床试验，比较177Lu-PSMA I＆T与激素治疗对转移性去势抵抗性前列腺癌患者的安全性和有效性。

The ECLIPSE trial enrolled over 400 patients, ahead of schedule, across 51 trial sites in the United States and Europe. Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium said: “We are proud to announce the completion of enrollment in the ECLIPSE trial, and would like to thank the patients, trial investigators, clinical research partners and our Curium cross-functional teams for their dedication and commitment.

ECLIPSE试验提前在美国和欧洲的51个试验点招收了400多名患者。Curium首席医疗官Sakir Mutevelic医学博士说：“我们很自豪地宣布完成ECLIPSE试验注册，并感谢患者，试验研究人员，临床研究合作伙伴和我们的Curium跨职能团队他们的奉献和承诺。

We are looking forward to delivering the study results once the data matures.” Michael Patterson, CEO, North America commented: “Curium is committed to advancing radioligand treatment options for patients with prostate cancer. Our proven ability to reliably manufacture and distribute nuclear medicine products across the globe is at the core of our business.

我们期待数据成熟后提供研究结果。”北美首席执行官Michael Patterson评论说：“Curium致力于推进前列腺癌患者的放射性配体治疗方案。我们在全球可靠制造和分销核医学产品的能力是我们业务的核心。

We are excited to continue to build on our trusted relationships with nuclear medicine physicians and their staffs while advancing the scientific knowledge leveraged by oncologists, radiation oncologists, and urologists to treat patients with metastatic castration-resistant prostate cancer.” For more information about the ECLIPSE trial (NCT05204927): www.eclipseclinicaltrial.org.

我们很高兴继续建立与核医学医生及其员工的信任关系，同时推进肿瘤学家，放射肿瘤学家和泌尿科医生利用的科学知识来治疗转移性去势抵抗性前列腺癌患者。”有关ECLIPSE试用版（NCT05204927）的更多信息：www.eclipseclinicaltrial.org。

For questions regarding the ECLIPSE Trial, please email: ECLIPSE@curiumpharma.com. About CuriumCurium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to h.

有关ECLIPSE试用版的问题，请发送电子邮件：ECLIPSE@curiumpharma.com.关于CuriumCurium是核医学领域的世界领导者。我们向h开发，制造和分销世界级放射性药物产品。